Emisphere Technologies’ EligenTechnology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal.
Emisphere Technologies is considering other potential licensees as well as the possibility of marketing the product without a partner.
Emisphere Technologies’ Eligen B12 1000mcg clinical study demonstrated that the drug is capable of quickly restoring Vitamin B12 levels in deficient individuals compared to the current standard of care.
Michael Novinski, president and CEO of Emisphere Technologies, said: “The process has been thorough but also time consuming. We want a commercial plan that will yield maximum value to our shareholders for this product, and at the same time provide flexibility for company growth and maximise value creation.”